Aytu BioPharma, Inc.

AYTU

Healthcare Drug Manufacturers Specialty & Generic

Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025.

Revenue
+6.42%
EPS
+100.0%
Free cash flow
+57.7%
Total debt
−21.9%

Quarter to June 2026, against a year earlier

1.83 0.02 +1.10%
Market cap
$19.9M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
3/9
ROIC
−20.0%
Net debt / EBITDA
2.2×
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 Jun '19 Jun '18 Jun '17
Total current assets
61.76 79.18 61.89 71.08 59.93 105.23 75.42 15.43 9.47 3.03
Total non-current assets
43.25 45.00 56.20 65.38 77.69 160.43 77.87 19.29 11.59 11.97
Total Assets
105.01 124.18 118.10 136.46 137.62 265.67 153.29 34.72 21.06 15.00
Total current liabilities
54.66 63.06 62.23 69.02 64.44 109.44 28.76 5.37 3.39 3.61
Total non-current liabilities
15.07 42.15 28.15 28.09 28.87 18.66 29.52 22.26 4.24 7.39
Total liabilities
69.73 105.21 90.38 97.11 93.32 128.10 58.28 27.63 7.64 11.00
Common Equity (Total)
35.27 18.97 27.72 39.36 44.31 137.57 95.02 7.09 13.42 4.00
Shareholders Equity (Total)
35.27 18.97 27.72 39.36 44.31 137.57 95.02 7.09 13.42 4.00
Total Debt
17.03 21.82 15.13 16.36 18.19 24.78 14.49 — — —

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 2 Nov 2026